There was a significant reduction in the concentration of GSH and activity of SOD in rats administered NAFLD as compared to the control rats, but this was significantly increased in rats treated with RUZU when compared to the control rats. The gene discussed is SOD1; the disease is metabolic dysfunction-associated steatotic liver disease.